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Abstract
Background: Although the human β-defensins hBDs today seem to have diverse functional
activities in innate antimicrobial immunity, a few reports also indicated an altered expression of
these antimicrobial peptides (AMPs) in tissues of cancers such as oral squamous cell carcinoma. The
present work was aimed on the study of hBD gene expression in basal cell carcinoma (BCC) which
is the most common cancer in humans.
Methods: Twenty-two non-ulcerated BCCs (12 nodular type, 10 superficial type) have been
analysed for the presence of hBD (1–3) mRNA by quantitative real-time RT-PCR. As controls, non-
lesional skin specimens of BCC patients as well as samples of healthy subjects were assessed by RT-
PCR.
Results: hBD-1 levels in healthy controls and non-lesional skin of BCC patients were significantly
(P < 0.05) higher than the levels observed in tumour tissue. Moreover, BCCs showed significantly
(P < 0.05) increased mRNA expression of hBD-2 as compared to controls. There was no significant
(P > 0.05) difference between lesional mRNA levels for hBD-3 and those levels observed in
controls. The mRNA expression of hBDs (1–3) found in nodular and superficial BCCs did not
significantly (P > 0.05) differ.
Conclusion: The gene expression patterns of hBD-1 and hBD-2 are for the first time shown to
be significantly altered in non-ulcerated BCCs as compared to intra-individual and inter-individual
controls, respectively. The present findings may indicate that beside the antimicrobial activity of
AMPs, hBDs may also play a role in the pathogenesis of BCC. However, functional and
immunohistological studies investigating hBDs in patients with BCC are needed to confirm our
data.
Background
Basal cell carcinoma (BCC) is the most common cancer in
humans. It is classified, together with squamous cell carci-
noma, as non-melanoma skin cancer. The incidence of
BCC is increasing worldwide by up to 10% a year.
Although mortality is low as BCC rarely metastasises, this
malignancy causes considerable morbidity and places a
huge burden on healthcare services worldwide. Three
main types of BCCs are generally distinguished with
regard to the histopathological growth pattern: nodular,
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superficial, and morphoeic. BCCs are believed to derive
from the epidermis, specifically the basal cell layer and the
outer root sheath of the hair follicle. The development of
BCC is clearly associated with mutated p53 tumour-sup-
pressor gene and constitutive activation of sonic hedge-
hog signalling molecules that regulate cell proliferation
and cell fate determination. Risk factors for the develop-
ment of BCC include advanced age, fair skin colour,
chronic ultraviolet exposure, and immunosuppression
[1,2].
BCCs are 10 times more common in persons who have
undergone a solid organ transplant and herpes-virus like
DNA sequences have been found in these tumours. The
possibility that certain types of human papilloma virus,
either alone or in conjunction with ultraviolet radiation,
may play a role in the pathogenesis of particular cancers is
suggested by several lines of evidence [3]. The human β-
defensins (hBDs) are antimicrobial peptides (AMPs)
mainly produced in skin by keratinocytes, neutrophils,
and mast cells. In addition to their strong antimicrobial
activity, hBDs may act as chemoattractant of neutrophils,
monocytes, and T lymphocytes [4]. Although hBDs today
seem to have diverse functional activities in innate antimi-
crobial immunity, a few reports also indicated an altered
expression of these AMPs in tissues of different cancers [5-
9]. In this pilot study we aimed to investigate the expres-
sion of hBDs in patients with BCC and healthy controls.
Methods
Subjects
In this prospective pilot study, 28 patients (16 men and
12 women; median age: 79.4; range: 64–96 years), who
were suspected of having non-ulcerated BCC on the basis
of clinical and dermoscopic features, underwent complete
tumour excision in our dermatologic surgery. Three milli-
metre punch biopsies were harvested from the centre of
the tumour (lesional) as well as an adjacent healthy skin
site approximately 1 cm in distance to the tumour border
(non-lesional controls). In addition to the BCC patient
group, we included 27 subjects (12 men and 15 women;
median age: 62.3 years; range: 27–83 years) who under-
went cosmetic surgery (healthy controls). Punch biopsies
were taken from the centre of excised skin tissue that was
otherwise rejected. We have not controlled age and gender
for the healthy subjects, since these parameters do not sig-
nificantly influence AMP expression. However, we sought
to obtain skin specimens from facial as well as body skin
in controls to exclude any bias that may arise from ana-
tomic variations of AMP expression [4]. The main portion
of each BCC specimen was fixed in formalin, routinely
processed, and embedded in paraffin. Sections were
stained with haematoxylin and eosin. All punch biopsy
specimens were processed for real-time RT-PCR analysis.
The study was conducted in the light of the declaration of
Helsinki. All patients who participated in the investiga-
tion signed an informed consent.
Real-time RT-PCR
Quantitative analysis of real-time RT-PCR was performed
as previously suggested [10]: total cellular RNA was iso-
lated from skin tissue samples using RNeasy® Lipid Tissue
Kit (QIAGEN, Chatsworth, CA) following the manufac-
turer's protocol. Prior to cDNA synthesis RNA was
digested with RNase-free DNase I (Roche Diagnostics,
North America). cDNA was synthesized by reverse tran-
scription from DNase I treated RNA using MultiScribe™
reverse transcriptase enzyme and random hexamers prim-
ers (TagMan® Reverse transcription reagents, Applied Bio-
systems, Forster City, CA). Real-time PCR was performed
using a Taqman SYBR Green PCR Master Mix and Gene-
Amp® Sequence Detection System (Applied Biosystems).
PCR Primers for AMPs and the Housekeeping Gene
(GAPDH) were designed using the computer program
Primer Express (PE Biosystems) and produced by the cus-
tom oligonucleotide synthesis service TIB Molbiol (Ger-
many). The primers for hBDs (1–3) and GAPDH are given
in Table 1. PCR amplifications were performed in a total
volume of 25 µl, containing 5 µl cDNA sample, 5 µM of
each primer and 12.5 µl SYBR Green PCR Master Mix. PCR
was started with 2 min at 50°C and an initial 10 min
denaturing temperature of 95°C, followed by a total of 40
cycles of 15 sec of denaturing and 1 min of annealing and
elongation at 60°C. The reaction products were separated
by 2% agarose gel electrophoresis (Fig. 1). Relative expres-
sion levels were calculated by the relative standard curve
method as outlined in the manufacturer's technical bulle-
tin. The comparative ∆-∆Ct method was used as previously
suggested by Livak and Schmittgen [11]. A standard curve
was generated using the fluorescent data from 10-fold
serial dilutions of total RNA of the highest expression
sample. This was then used to calculate the relative
amounts of target mRNA in test samples. Quantities of all
targets in the test samples were normalized to the corre-
sponding GAPDH RNA transcript in the skin samples. In
order to make the quantities of mRNA levels more illus-
trative, the ∆Ct values (logarithms) were re-transformed.
Statistics
Data analysis was performed using the statistical package
MedCalc Software (Mariakerke, Belgium). Non-normal
distribution of data was confirmed by the D'Agostino-
Pearson test. Hence, data were expressed in medians and
lowest and highest values (range). The results were ana-
lysed using paired or independent non-parametric tests
including the Wilcoxon-rank test and the Mann-Whitney
test. We constrained experiment-wise error rates due to
multiple comparisons to the standard alpha (P) level of <
0.05 by the Bonferroni method.BMC Cancer 2006, 6:163 http://www.biomedcentral.com/1471-2407/6/163
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Results
Fifteen of the BCCs investigated were localised on the face
and 13 on the trunk and lower extremities. Histological
examination revealed 18 nodular BCCs and 10 superficial
BCCs. Six of the nodular BCCs on the face showed ulcera-
tion on histology and were therefore excluded from fur-
ther evaluation. In the control group, we harvested 11
biopsies from the face and 16 on the trunk and lower
extremities. The medians and range of mRNA expression
of AMPs in BCC patients (n = 22) and healthy controls (n
= 27) are shown in Fig. 2 and Table 1, respectively. The
mRNA levels of hBDs (1–3) observed in healthy skin of
controls did not significantly (P > 0.05) differ from non-
lesional hBD levels of BCCs patients. However, hBD-1 lev-
els in healthy controls and non-lesional skin were signifi-
cantly (P < 0.05) higher than the hBD-1 levels observed in
BCCs. Moreover, BCCs showed significantly (P < 0.05)
increased mRNA expression of hBD-2 as compared to
healthy controls and non-lesional skin. There was no sig-
nificant (P > 0.05) difference between lesional mRNA lev-
els for hBD-3 and those levels observed in healthy
controls and non-lesional skin. The mRNA expression of
hBDs (1–3) found in nodular and superficial BCCs did
not significantly (P > 0.05) differ (hBD-1: 0.140 vs 0.290;
hBD-2: 0.061 vs 0.0451; hBD-3: 0.050 vs 0.028).
Discussion
Current information on AMP structure, expression, and
biologic activity has established a firm foundation for fur-
ther study of the impact that these peptides might have in
human disease. For example, human α-defensin (hAD)
expression has previously been linked to different types of
tumours and cell lines. hAD-1 has been detected in lung
tumours and in the submandibular glands of patients
with oral carcinomas. By RT-PCR, mass spectrometry and
flow cytometric analysis, hADs (1–3) have been shown to
be expressed by cell lines deriving from renal cell carcino-
mas and the expression of a specific hAD precursor pep-
tide has been shown to be upregulated in human
leukemic cells. It has been suggested that hADs could
belong to tumour substrates that modulate malignant cell
growth and enhance immune escape in tumours [12-14].
Moreover, several reports recently indicated an altered
expression of hBDs in tissues of different cancers includ-
ing oral squamous cell carcinoma, lung cancer, renal and
prostatic carcinoma, and vulval cancer. However, to our
best knowledge, there are no reports exploring the signifi-
cance of AMPs in the pathogenesis of skin cancer such as
BCC [5-9].
We have shown that mRNA expression of hBDs insignifi-
cantly differ between non-lesional skin of BCC patients
and healthy controls indicating that there exists no consti-
tutional difference in hBD gene expression. Nevertheless,
we observed significantly altered expression of hBD-1 and
hBD-2 in BCCs as compared to controls. The alterations
observed in BCCs were however independent from
tumour subtypes. The hBD gene expression patterns
observed in BCCs do not appear to be substantially differ-
ent from those seen in inflammatory conditions such as
atopic dermatitis and psoriasis [4,15,16]. HBD-1 belongs
to the constitutive β-defensins which has been observed
in normal epidermis. However, hBD-1 is not increased in
response to inflammation, as is hBD-2, and displays anti-
microbial activity against Gram-positive and Gram-nega-
tive bacteria, as well as viral agents [4,15]. Interestingly,
we found significantly decreased mRNA levels of hBD-1 in
BCC possibly indicating that expression of this constitu-
tive AMP is markedly downregulated in tumour tissue.
Notably, in previous gene expression profiling studies of
renal epithelial neoplasms, hBD-1 was found to be signif-
icantly downregulated in conventional clear cell carci-
noma [7]. In contrast to its weak antimicrobial activity,
hBD-1 has a strong cytotoxic potential toward mamma-
lian cells, leading to speculation that hBD-1 had functions
other than the antimicrobial activity so characteristic of
other defensins [7,17]. Furthermore, the expression of
hBD-1 early in development suggests that it has physio-
logic functions rather than only host microbial defense.
Considering the existing literature together with the data
presented in this paper, one my speculate that hBD-1 may
contribute to host antitumour immunity or otherwise
function as a tumour suppressor gene. If hBD-1 expres-
sion is lost at some point during the malignant transfor-
mation, the host may be less likely to recognize the
tumour as "foreign", and the tumour may be more likely
PCR products of hBDs and housekeeping gene (GAPDH) on  2% agarose gels Figure 1
PCR products of hBDs and housekeeping gene (GAPDH) on 
2% agarose gels. BMC Cancer 2006, 6:163 http://www.biomedcentral.com/1471-2407/6/163
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to survive [7]. Nevertheless, our data do not address these
functional questions.
The virtual absence of hBD-2 in controls observed in the
present study, gives support to previous reports that this
AMP is not normally produced but are upregulated under
pathological conditions such as inflammation (e.g., bac-
terial infection, atopic eczema, psoriasis) and malignan-
cies (e.g., oral squamous carcinoma). We have
demonstrated that hBD-2 levels are significantly upregu-
lated in BCC. Although we sought to include into the
study only BCC without evidence of ulceration, we cannot
fully exclude that impairment of skin barrier functions
associated with an increased invasion of microbes, con-
tributed to the upregulation of hBD-2 in tumour tissue
investigated. Whereas impairment of skin barrier func-
tions are common in BCC, it has been demonstrated that
germ colonization of BCC lesions is usually indifferent
from normal skin [18,19]. Yoshimoto et al. [5] performed
a study on oral squamous cell carcinoma and found that
the expression of hBD-2 was observed not only in
inflamed lesions with bacterial infection but also in the
non-inflamed carcinomas themselves. The authors con-
cluded that hBD-2 might play a role in squamous cell car-
cinoma, which is different from the native defensive role
of AMP. Indeed, one may speculate that hBD-2 could lead
to the death of normal keratinocytes adjacent to the
tumour, which might, in turn, indirectly assist in the mul-
tiplication of malignant cells [5,9]. Unlike hBD-1 and
hBD-2, lesional hBD-3 levels insignificantly differed from
controls as observed in the present study. Shnitsar et al.
[8] recently investigated hBD-3 gene expression in A431
cell line and human vulval tumours. Interestingly, they
found that in human vulval epithelium, the increase in
hBD-3 mRNA expression was predominantly associated
with malignant phenotype.
Conclusion
The gene expression patterns of hBD-1 and hBD-2 are for
the first time shown to be significantly altered in non-
ulcerated BCCs as compared to intra-individual and inter-
individual controls, respectively. The heterogeneity of
hBD expression in BCC indicates that beside the antimi-
crobial activity of AMPs, hBDs have other unique func-
tions that may also play a role in the pathogenesis of BCC.
The altered expression of hBDs by transformed keratinoc-
ytes may impair host immune recognition and control of
cellular proliferation and/or differentiation [20,21]. The
Diagram showing levels of median mRNA expression of hBDs in lesional and non-lesional skin of 22 patients with non-ulcer- ated basal cell carcinoma.  Figure 2
Diagram showing levels of median mRNA expression of hBDs in lesional and non-lesional skin of 22 patients 
with non-ulcerated basal cell carcinoma. hBD mRNA expression in 27 healthy controls is also shown. mRNA expression 
levels given on the y-axis correspond to the re-transformed logarithms of the ∆Ct values.
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altered expression of hBDs in epithelial cancers such as
BCC, on the other hand, could also be a result of impaired
proliferation and/or differentiation of keratinocytes
[5,8,9]. However, this was not specifically investigated in
our study. Indeed, limitations of the present trial do not
only include the absence of functional, but also immuno-
histological studies. The latter could confirm the presence
and localisation of differentially expressed genes on the
protein level as well. Hence, our results have to be sub-
stantiated by functional and immunohistological investi-
gations on hBDs in patients with BCC.
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